Table 3.

Proportions of patients with MADRS response, MADRS remission, and CGI-BP-C response at the end of treatment

		Placebo group (n = 177)	Quetiapine XR 300 mg group (n = 179)
Patients with a response based on MADRS total score		63 (35.6%)	79 (44.1%)
Patients with a remission based on MADRS total score		47 (26.6%)	68 (38.0%)
Patients with a response based on CGI-BP-C score	Overall bipolar illness	64 (36.2%)	77 (43.0%)
	Depression	65 (36.7%)	77 (43.0%)
	Mania	1 (0.6%)	2 (1.1%)

n (%)

MADRS Montgomery-Åsberg Depression Rating Scale, CGI-BP-C Clinical Global Impressions-Bipolar-Change